Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors.

Third Quarter 2008 Results Conference Call 06-09-08

ONCONASE Phase IIIb Clinical Trial Prelim. Data Update 05-29-08

Second Quarter 2008 Results Conference Call and Webcast 03-07-08

First Quarter 2008 Results Conference Call and Webcast 12-10-07

Webcast of RNA Interference-Like Mechanics of RNase Therapeutics 11-29-07

Webcast of Alfacell at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 11-05-07

Webcast of Alfacell Fiscal Year End and Fourth Quarter 2007 Results Conference Call 10-15-07

Webcast of Alfacell at Biotechnology Industry Organization Investor Forum 10-11-07

Webcast of Alfacell Corporation Presentation at the UBS 2007 Global Life Sciences Conference 9-26-07

Webcast of Alfacell Corporation Presentation at the Noble Financial Two Double-O-Seven Conference 8-20-07

Webcast of Alfacell Corporation Presentation at the C.E. Unterberg Towbin Emerging Growth Opportunities Conference 7-12-2007